MX387639B - Formulaciones farmacéuticas de compuesto de piridinio y un potenciador de la permeabilidad o una base. - Google Patents

Formulaciones farmacéuticas de compuesto de piridinio y un potenciador de la permeabilidad o una base.

Info

Publication number
MX387639B
MX387639B MX2017012942A MX2017012942A MX387639B MX 387639 B MX387639 B MX 387639B MX 2017012942 A MX2017012942 A MX 2017012942A MX 2017012942 A MX2017012942 A MX 2017012942A MX 387639 B MX387639 B MX 387639B
Authority
MX
Mexico
Prior art keywords
pharmaceutical formulations
base
permeability enhancer
formulations
pyridinium compound
Prior art date
Application number
MX2017012942A
Other languages
English (en)
Other versions
MX2017012942A (es
Inventor
Amit Kesarwani
Anita Chaudhari
Anoop Mathur
Chaitanya Dutt
Jaya Abraham
Jignesh Kotecha
Manish Patel
Ramesh Chandra Gupta
Sachin Latad
Shailesh Deshpande
Shital Kumar Zambad
Vivek Mishra
Original Assignee
Torrent Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrent Pharmaceuticals Ltd filed Critical Torrent Pharmaceuticals Ltd
Publication of MX2017012942A publication Critical patent/MX2017012942A/es
Publication of MX387639B publication Critical patent/MX387639B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta invención se refiere a formulaciones farmacéuticas que comprenden 1-(2-tien-2'-il-2-oxo-etil)-3-(metansulfonil-hidrazina carbonil) piridinio, sus sales farmacéuticamente aceptables, sal-cocristales y cocristales, particularmente cloruro de 1-(2-tien-2'-il-2-oxo-etil)-3-(metansulfonil-hidrazina-carbonil) piridinio. Las formulaciones son adecuadas para la administración oral y también comprenden un potenciador de la permeabilidad o una base adecuada o una mezcla de los mismos. Las formulaciones de esta invención son para tratar enfermedades asociadas con productos finales de glicación avanzada.
MX2017012942A 2015-04-08 2016-04-05 Formulaciones farmacéuticas de compuesto de piridinio y un potenciador de la permeabilidad o una base. MX387639B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1475MU2015 2015-04-08
PCT/IB2016/051920 WO2016162787A1 (en) 2015-04-08 2016-04-05 Pharmaceutical formulations

Publications (2)

Publication Number Publication Date
MX2017012942A MX2017012942A (es) 2018-01-30
MX387639B true MX387639B (es) 2025-03-18

Family

ID=55808800

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017012942A MX387639B (es) 2015-04-08 2016-04-05 Formulaciones farmacéuticas de compuesto de piridinio y un potenciador de la permeabilidad o una base.

Country Status (31)

Country Link
US (1) US10772879B2 (es)
EP (1) EP3280447B1 (es)
JP (1) JP6736656B2 (es)
KR (1) KR20170134662A (es)
CN (1) CN107530287B (es)
AR (1) AR104185A1 (es)
AU (1) AU2016246124B2 (es)
BR (1) BR112017021669A2 (es)
CA (1) CA2997463A1 (es)
CY (1) CY1121921T1 (es)
DK (1) DK3280447T3 (es)
EA (1) EA037041B1 (es)
ES (1) ES2724629T3 (es)
HR (1) HRP20190783T1 (es)
HU (1) HUE044889T2 (es)
IL (1) IL254794B (es)
LT (1) LT3280447T (es)
MX (1) MX387639B (es)
MY (1) MY182008A (es)
PH (1) PH12017501829A1 (es)
PL (1) PL3280447T3 (es)
PT (1) PT3280447T (es)
RS (1) RS58708B1 (es)
SG (1) SG11201708142XA (es)
SI (1) SI3280447T1 (es)
SM (1) SMT201900264T1 (es)
TR (1) TR201906476T4 (es)
TW (1) TWI713512B (es)
UA (1) UA123051C2 (es)
WO (1) WO2016162787A1 (es)
ZA (1) ZA201707094B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014007972A2 (en) 2012-06-15 2014-01-09 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinphrine
DK2976072T3 (da) 2013-03-22 2021-08-16 Univ Nova Southeastern Epinephrinfinpartikler og fremgangsmåder til anvendelse deraf til behandling af tilstande, der reagerer på epinephrin
JP7657457B2 (ja) * 2018-10-19 2025-04-07 ノバ サウスイースタン ユニバーシティー ｐＨ修飾賦形剤及び浸入促進剤を含む舌下エピネフリン組成物及びそれを使用する方法
PL3949952T3 (pl) 2019-04-03 2024-10-14 Astellas Pharma Inc. Kompozycja farmaceutyczna
KR102330597B1 (ko) * 2020-04-17 2021-11-26 보령제약 주식회사 무정형의 엠파글리플로진을 포함하는 안정성이 향상된 신규 약제학적 제형
KR20220080880A (ko) * 2020-12-08 2022-06-15 주식회사 종근당 엠파글리플로진 공결정을 함유하는 약제학적 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000050012A1 (en) * 1999-02-22 2000-08-31 Elan Corporation, Plc Solid oral dosage form containing an enhancer
EP1222171B1 (en) * 1999-10-06 2004-02-25 Torrent Pharmaceuticals Ltd Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof
DK1243581T3 (da) 2001-03-21 2005-10-31 Torrent Pharmaceuticals Ltd Pyridiniumforbindelser til behandling af AGE-relaterede sygdomme
BRPI0708507A2 (pt) 2006-03-03 2011-05-31 Torrent Pharmaceuticals Ltd Novos antagonistas de receptores de dupla ação (dara) para os receptores at1 eta
JP2009023932A (ja) * 2007-07-18 2009-02-05 Tama Tlo Kk Ｎ−メチルピリジニウム化合物を有効成分として含有する抗ウイルス剤、それを含有する、抗ウイルス組成物、食餌及び動物用飼料
RU2010135524A (ru) * 2008-01-25 2012-02-27 Торрент Фармасьютикалз Лтд. (In) Фармацевтические комбинации
CN101574343B (zh) * 2008-05-07 2011-06-01 吉林大学 一种治疗糖尿病的药物组合物
CA2764232A1 (en) * 2009-05-07 2010-11-11 Torrent Pharmaceuticals Limited Novel heterocyclic compounds
JP2013514976A (ja) * 2009-12-16 2013-05-02 ノッド ファーマシューティカルズ， インコーポレイテッド 経口薬物送達のための組成物および方法
CN104069066B (zh) * 2013-03-25 2017-04-19 吉林大学 黄癸固体分散体及其在治疗糖尿病及并发症中的应用

Also Published As

Publication number Publication date
AU2016246124B2 (en) 2019-11-14
IL254794A0 (en) 2017-12-31
HUE044889T2 (hu) 2019-11-28
SI3280447T1 (sl) 2019-06-28
CN107530287A (zh) 2018-01-02
ZA201707094B (en) 2021-04-28
TR201906476T4 (tr) 2019-05-21
US10772879B2 (en) 2020-09-15
MY182008A (en) 2021-01-18
UA123051C2 (uk) 2021-02-10
TWI713512B (zh) 2020-12-21
CN107530287B (zh) 2020-11-10
AR104185A1 (es) 2017-07-05
JP6736656B2 (ja) 2020-08-05
EA201792237A1 (ru) 2018-02-28
HRP20190783T1 (hr) 2019-06-28
AU2016246124A1 (en) 2017-11-02
RS58708B1 (sr) 2019-06-28
WO2016162787A1 (en) 2016-10-13
IL254794B (en) 2021-05-31
KR20170134662A (ko) 2017-12-06
DK3280447T3 (da) 2019-05-13
EP3280447B1 (en) 2019-02-27
EA037041B1 (ru) 2021-01-29
ES2724629T3 (es) 2019-09-12
PH12017501829A1 (en) 2018-04-23
MX2017012942A (es) 2018-01-30
SMT201900264T1 (it) 2019-07-11
SG11201708142XA (en) 2017-11-29
TW201642858A (zh) 2016-12-16
PL3280447T3 (pl) 2019-07-31
PT3280447T (pt) 2019-05-14
LT3280447T (lt) 2019-05-27
US20180110763A1 (en) 2018-04-26
EP3280447A1 (en) 2018-02-14
CY1121921T1 (el) 2020-10-14
JP2018510916A (ja) 2018-04-19
BR112017021669A2 (pt) 2018-07-10
CA2997463A1 (en) 2016-10-13

Similar Documents

Publication Publication Date Title
CY1123810T1 (el) Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
CY1124669T1 (el) ΑΝΤΙ-ΟΙΣΤΡΟΓΟΝΙΚΑ ΦΑΡΜΑΚΑ ΤΕΤΡΑΫΔΡΟ-1Η-ΠΥΡΙΔΟ[3,4-b]INΔOΛIOY
JOP20200001A1 (ar) كاربوكسأميدات بوصفها معدلات لقنوات الصوديوم
JOP20200154A1 (ar) مركبات ومشتقات بيريدو بيريمينون بها استبدال ببنزيل أمينو جديدة كمثبطات sos1
CY1124084T1 (el) Αμιδο-υποκατεστημενα παραγωγα πυριδινυλοτριαζολης και χρησεις αυτων
PH12017501829A1 (en) Pharmaceutical formulations
CY1120903T1 (el) Ενωσεις αμινοπυριδυλοξυπυραζολιου
EA201892119A1 (ru) Лекарственный препарат, полученный путем комбинирования агониста fxr и arb
SA518400356B1 (ar) مثبطات الأرجيناز واستخداماتها العلاجية
DOP2017000306A (es) Formulaciones farmacéuticas que contienen tenofovir y emtricitabina
CY1124907T1 (el) Αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
AR100663A1 (es) Formulaciones de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
MX2020007552A (es) Composicion farmaceutica estable que comprende esomeprazol y bicarbonato de sodio.
EA201890532A1 (ru) Новые аннелированные бензамиды
PH12020550125A1 (en) Crystalline forms of 3-substituted 1,2,4-oxadiazole
EA201692298A1 (ru) Производные карбоксамидов
EA201891682A1 (ru) Производное азациклического амида, способ его получения и фармацевтическое применение
TN2018000214A1 (en) Alkyl dihydroquinoline sulfonamide compounds
EA201991286A1 (ru) Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
MX385513B (es) Composiciones farmaceuticas que comprenden safinamida.
BR112018003335A2 (pt) composições farmacêuticas compreendendo 3-(5-amino-2-metil-4-oxo-4h-quinazolina-3-il)-piperidina-2,6-diona
PH12016502527B1 (en) Stabilized desmopressin
TH176362A (th) สารประกอบ องค์ประกอบทางเภสัชกรรม และการใช้สิ่งดังกล่าวในการบำบัด โรคการเสื่อมของระบบประสาท